Sector News

GSK to shutter Ermington plant in Australia by 2020

November 9, 2016
Life sciences

Pharma giant GlaxoSmithKline said it plans to shutter its over-the-counter consumer healthcare manufacturing facility in Ermington, Australia, by 2020. The closure will affect about 223 jobs, the company said.

The plant, which is located on the outskirts of Sydney, produces liquid and tablet cold and flu drugs mostly for the Australian market.

Citing a review of the facility that indicated it would not be able to remain competitive in the future without a “significant investment,” the company said it will institute a phased closure over the next four years that will include the transfer of some production to other GSK plants or to CMOs.

The closure of the Ermington plant isn’t expected to impact other GSK operations in the country, which include the manufacturing site in Boronia that produces respiratory products.

“We have thoroughly evaluated a number of options before taking the decision to close the site, but unfortunately significant ongoing investment would be needed to maintain our Ermington manufacturing facility, making it uncompetitive to keep manufacturing in Ermington in the future,” Michael Tyler, GSK’s vice president of supply chain in Asia, the Middle East and Africa, said in a statement.

Late last year, GSK opened a cutting-edge $5.7 million blow-fill-seal plant in Boronia, outside of Melbourne. That opening came on the heels of the company selling two opiate manufacturing sites to Indian generics maker Sun Pharma that are located in Latrobe, Tasmania, and Port Fairy, Victoria.

By Joseph Keenan

Source: Fierce Pharma

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.